Tue. 16 Apr 2024, 4:14pm ET
Benzinga
News
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy. Patients identified across all six TCR-T cohorts in solid tumor program with dosing of first three expected in early May. All eight patients in the heme program treated with TSC-100 or TSC-101 remain relapse-free with no detectable cancer to date; median follow-up of >10 months.